Department of Hematology
Jeroen J.W.M. Janssen has not added Biography.
If you are Jeroen J.W.M. Janssen and would like to personalize this page please email our Author Liaison for assistance.
Bone marrow stromal proteoglycans regulate megakaryocytic differentiation of human progenitor cells.
Experimental cell research Oct, 2004 | Pubmed ID: 15350537
Reduced supportive capacity of bone marrow stroma upon chemotherapy is mediated via changes in glycosaminoglycan profile.
Matrix biology : journal of the International Society for Matrix Biology Sep, 2007 | Pubmed ID: 17521897
Towards cure of CML: why we need to know more about CML stem cells?
Current stem cell research & therapy Sep, 2009 | Pubmed ID: 19492977
A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
American journal of hematology Oct, 2009 | Pubmed ID: 19658186
Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands.
Annals of hematology Sep, 2010 | Pubmed ID: 20383504
Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells.
Haematologica Jun, 2010 | Pubmed ID: 20421276
Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells.
Immunotherapy Apr, 2011 | Pubmed ID: 21463196
Clinical validation of dried blood spot sampling in therapeutic drug monitoring of ciclosporin A in allogeneic stem cell transplant recipients: direct comparison between capillary and venous sampling.
Therapeutic drug monitoring Feb, 2013 | Pubmed ID: 23296096
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Annals of hematology Aug, 2013 | Pubmed ID: 23572137
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).
European journal of cancer (Oxford, England : 1990) Oct, 2013 | Pubmed ID: 23876833
Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia.
BMC cancer Apr, 2014 | Pubmed ID: 24712728
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia.
Haematologica Jan, 2016 | Pubmed ID: 26721801
Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis.
Journal of cancer research and clinical oncology Jul, 2017 | Pubmed ID: 28224300
Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling.
The Journal of pharmacy and pharmacology Oct, 2017 | Pubmed ID: 28643375
Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival.
European journal of haematology Oct, 2017 | Pubmed ID: 28718971
Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.
Haematologica Nov, 2017 | Pubmed ID: 28860339
Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival.
Haematologica Dec, 2017 | Pubmed ID: 28860340
Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation.
BMC cancer Nov, 2017 | Pubmed ID: 29121889
Patient satisfaction with information on oral anticancer agent use.
Cancer medicine Jan, 2018 | Pubmed ID: 29168352
Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.
Critical reviews in oncology/hematology Dec, 2017 | Pubmed ID: 29198338
Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.
European journal of haematology Dec, 2017 | Pubmed ID: 29288559
Jacqueline Cloos*,1,2,
Jeffrey R. Harris*,3,
Jeroen J.W.M. Janssen1,
Angele Kelder1,
F. Huang3,
Gerrit Sijm1,
Maike Vonk1,
Alexander N. Snel1,
Jennifer R. Scheick1,
Willemijn J. Scholten1,
Jannemieke Carbaat-Ham1,
Dennis Veldhuizen1,
Diana Hanekamp1,
Yvonne J.M. Oussoren-Brockhoff1,
Gertjan J.L. Kaspers2,4,
Gerrit J. Schuurhuis1,
A. Kate Sasser3,
Gert Ossenkoppele1